Lanthio Pharma is focused on discovering and developing lantipeptide drugs for serious diseases. We are working on lanthipeptides as new treatment for fibrosis, stroke, heart failure and multiple sclerosis. To discover and produce drug candidates, we apply our proprietary LanthioPep technology. This technology uses modified Lactococcus bacteria to make constrained peptides, called lanthipeptides. Our lanthipeptides are more disease target selective and more stable in plasma compared to linear wild-type peptides, making them more suitable as drug candidates.